New studies show that aged gut microbes drive systemic aging via extracellular vesicles, while pulsed ultrasound restores microbiome diversity and improves muscle function in mice. Aging gut microbes ...
UDP-003, a cyclodextrin-based drug, safely reduces 7-ketocholesterol in Phase 1, potentially reversing atherosclerosis instead of just slowing it. A novel drug that removes toxic cholesterol byproduct...
Recent studies reveal that immune aging, or ‘inflammaging,’ is a modifiable risk factor for neurodegenerative diseases, with new biomarkers and senolytic drugs offering hope for early inte...
Dermatology is shifting from surface-level cosmetics to biology-driven interventions targeting aging hallmarks, with senolytics, epigenetic reprogramming, and biomimetic peptides leading the charge. D...
Phase 1 data for BGE-102 demonstrates significant reductions in hsCRP and inflammatory biomarkers, positioning it as a potential best-in-class therapy for cardiovascular risk and age-related inflammat...
Life Biosciences launches a Phase I trial for cellular reprogramming to treat age-related macular degeneration, challenging aging norms with FDA’s Plausible Mechanism Pathway, amid rising invest...
uPAR-targeted CAR T cell therapy shows promising results in solid tumors, with recent clinical trials and FDA designations advancing cancer immunotherapy towards precision medicine. Recent advancement...
Muscle-generated exerkines in extracellular vesicles are crucial for exercise-induced health, with new research suggesting therapies for sarcopenia and metabolic diseases through inter-organ communica...
New research shows that enzyme Pck1 depletion drives senescence in fat cells, causing insulin resistance and inflammaging, highlighting it as a promising target for age-related metabolic diseases. A r...
Recent studies show encapsulated mitochondria delivery using red blood cell membranes improves motor function and neuron survival in Parkinson’s disease models, offering hope for mitochondrial d...
